PPC
MCID: PRM126
MIFTS: 61

Primary Peritoneal Carcinoma (PPC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Primary Peritoneal Carcinoma

MalaCards integrated aliases for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 58 36 70
Serous Surface Papillary Carcinoma 58 70
Extra-Ovarian Primary Peritoneal Carcinoma 58
Primary Peritoneal Serous Adenocarcinoma 70
Primary Peritoneal Serous Carcinoma 58
Eoppc 58
Ppc 58

Characteristics:

Orphanet epidemiological data:

58
primary peritoneal carcinoma
Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

KEGG 36 H01665
ICD10 via Orphanet 33 C48.2
Orphanet 58 ORPHA168829
UMLS 70 C0334361 C1514428 C1514429

Summaries for Primary Peritoneal Carcinoma

KEGG : 36 Female primary peritoneal carcinoma (PPC) has the characteristic of diffuse involvement of the peritoneum by papillary carcinoma in the absence of an obvious primary site and grossly normal ovaries, or minimal involvement. It is histologically indistinguishable from primary epithelial ovarian carcinoma (EOC) and is diagnosed in the absence of another identifiable primary. Most reported PPC cases are primary peritoneal serous papillary carcinoma (PPSPC), while peritoneal mixed epithelial carcinoma (MEC) and malignant mixed Mullerian tumor (MMMT) are rarely reported. Germline BRCA1 mutations in 26% of PPSPC patients was detected. BRCA1 mutation carriers had a higher overall incidence of p53 mutations than wildtype BRCA1 case subjects. It is suggested that p53 has a unique role in the development and progression of BRCA1-related PPSPC.

MalaCards based summary : Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to stomatitis and familial ovarian cancer. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Sodium citrate and Thalidomide have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and skin, and related phenotypes are nausea and vomiting and constipation

Wikipedia : 73 Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary... more...

Related Diseases for Primary Peritoneal Carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 467)
# Related Disease Score Top Affiliating Genes
1 stomatitis 30.4 IL10 IFNG CXCL8
2 familial ovarian cancer 30.4 BRCA2 BRCA1
3 inflammatory breast carcinoma 30.2 PGR ERBB2 EGFR
4 peritonitis 30.1 MUC16 IL10 CXCL8
5 papillary carcinoma 29.9 RET PGR ERBB2
6 severe acute respiratory syndrome 29.9 IL10 IFNG CXCL8 CXCL10
7 exanthem 29.8 VEGFA IL10 IFNG ERBB2 EGFR CXCL8
8 papillary serous adenocarcinoma 29.6 TP53 PGR BRCA2 BRCA1
9 prostatitis 29.6 TP53 IL10 CXCL8
10 endometriosis 29.5 VEGFA PGR MUC16 CXCL8
11 papilloma 29.5 VEGFA TP53 ERBB2 EGFR
12 hereditary breast ovarian cancer syndrome 29.5 TP53 ERBB2 BRCA2 BRCA1
13 suppression of tumorigenicity 12 29.5 VEGFA TP53 ERBB2 EGFR
14 glioma 29.4 TP53 ERBB2 EGFR BRCA2
15 ovarian cystadenocarcinoma 29.3 TP53 MUC16 ERBB2 EGFR BRCA2 BRCA1
16 carcinosarcoma 29.3 TP53 PGR ERBB2 EGFR
17 fallopian tube carcinoma 29.3 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
18 in situ carcinoma 28.9 TP53 PGR ERBB2 EGFR BRCA2 BRCA1
19 cystadenocarcinoma 28.9 VEGFA TP53 PGR MUC16 ERBB2 BRCA1
20 ovary epithelial cancer 28.8 VEGFA TP53 MUC16 ERBB2 EGFR BRCA2
21 eye disease 28.8 VEGFA TP53 IL10 IFNG CXCL8 CXCL10
22 adenocarcinoma 28.8 VEGFA TP53 RET ERBB2 EGFR BRCA2
23 serous cystadenocarcinoma 28.6 VEGFA TP53 PGR MUC16 ERBB2 BRCA2
24 peripheral nervous system disease 28.6 VEGFA TP53 IL10 IFNG ERBB2 EGFR
25 malignant ovarian surface epithelial-stromal neoplasm 28.4 VEGFA TP53 PGR MUC16 ERBB2 EGFR
26 ovarian disease 28.4 VEGFA TP53 PGR MUC16 ERBB2 BRCA2
27 ovary adenocarcinoma 28.2 VEGFA TP53 PGR MUC16 ERBB2 EGFR
28 ovarian cancer 27.8 VEGFA TP53 PGR MUC16 MIR195 IL10
29 endometrial cancer 27.6 VEGFA TP53 RET PGR MUC16 ERBB2
30 prostate cancer 27.1 VEGFA TP53 PGR MIR497 MIR195 IL10
31 colorectal cancer 26.7 VEGFA TP53 RET MUC16 MIR497 MIR195
32 ovary papillary carcinoma 11.4
33 ovarian epithelial cancer 10.5
34 fallopian tube clear cell adenocarcinoma 10.4 BRCA2 BRCA1
35 ovary transitional cell carcinoma 10.4 BRCA2 BRCA1
36 cancerophobia 10.4 BRCA2 BRCA1
37 nosophobia 10.4 BRCA2 BRCA1
38 tetraploidy 10.4 BRCA2 BRCA1
39 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 10.4 BRCA2 BRCA1
40 ruvalcaba syndrome 10.4 BRCA2 BRCA1
41 hereditary site-specific ovarian cancer syndrome 10.4 BRCA2 BRCA1
42 neutropenia 10.4
43 breast juvenile papillomatosis 10.3 ERBB2 BRCA2
44 acute transverse myelitis 10.3 IL10 CXCL8
45 acute cervicitis 10.3 IL10 CXCL8
46 acute gonococcal cervicitis 10.3 IL10 CXCL8
47 fuchs' heterochromic uveitis 10.3 IFNG CXCL8
48 breast-ovarian cancer, familial 2 10.3 BRCA2 BRCA1
49 spotted fever rickettsiosis 10.3 IL10 IFNG
50 submandibular gland cancer 10.2 ERBB2 EGFR

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to Primary Peritoneal Carcinoma

Symptoms & Phenotypes for Primary Peritoneal Carcinoma

Human phenotypes related to Primary Peritoneal Carcinoma:

58 31 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 constipation 58 31 hallmark (90%) Very frequent (99-80%) HP:0002019
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
4 neoplasm 58 31 hallmark (90%) Very frequent (99-80%) HP:0002664
5 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
6 peritonitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002586

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
2 embryo MP:0005380 10.28 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
3 cardiovascular system MP:0005385 10.27 BRCA1 CXCL10 EGFR ERBB2 IFNG IL10
4 endocrine/exocrine gland MP:0005379 10.26 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
5 hematopoietic system MP:0005397 10.25 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
6 immune system MP:0005387 10.24 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
7 digestive/alimentary MP:0005381 10.2 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
8 integument MP:0010771 10.18 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
9 neoplasm MP:0002006 10.14 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
10 muscle MP:0005369 10.13 BRCA1 EGFR ERBB2 ERCC1 IFNG IL10
11 limbs/digits/tail MP:0005371 10.11 BRCA1 BRCA2 EGFR ERBB2 IL10 PGR
12 nervous system MP:0003631 10.11 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
13 normal MP:0002873 9.96 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
14 reproductive system MP:0005389 9.9 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
15 no phenotypic analysis MP:0003012 9.87 EGFR IFNG IL10 PGR RET TP53
16 respiratory system MP:0005388 9.56 BRCA1 EGFR ERBB2 IFNG IL10 RET
17 skeleton MP:0005390 9.32 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG

Drugs & Therapeutics for Primary Peritoneal Carcinoma

Drugs for Primary Peritoneal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 3 68-04-2
2
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
3
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
10 Citrate Phase 3
11 Gastrointestinal Agents Phase 3
12 Antimitotic Agents Phase 3
13 Tubulin Modulators Phase 3
14 Immunologic Factors Phase 3
15 Antineoplastic Agents, Immunological Phase 3
16 Immunoglobulin G Phase 3
17 Antibodies Phase 3
18 Immunoglobulins, Intravenous Phase 3
19 Mitogens Phase 3
20 Immunoglobulins Phase 3
21 Angiogenesis Inhibitors Phase 3
22 Antibodies, Monoclonal Phase 3
23 Endothelial Growth Factors Phase 3
24 Albumin-Bound Paclitaxel Phase 3
25 Anti-Infective Agents Phase 3
26 Antiviral Agents Phase 3
27 interferons Phase 3
28 Interferon-gamma Phase 3
29
Metformin Approved Phase 2 657-24-9 4091 14219
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
32
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
33
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
34
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
35
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
36
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
37
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
38
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
39
Catumaxomab Approved, Investigational, Withdrawn Phase 2 509077-98-9
40
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
41
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
42
Nintedanib Approved Phase 2 656247-17-5 56843413
43
ramucirumab Approved, Investigational Phase 2 947687-13-0
44
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
45
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
46
tannic acid Approved Phase 2 1401-55-4
47
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
48
Olaparib Approved Phase 2 763113-22-0 23725625
49
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
50
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
2 A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
3 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
4 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
5 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
6 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
7 Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT01704651 Phase 3 Alvimopan;Placebo
8 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
9 A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of DCVAC/OvCa Added to Standard of Care in Patients With Relapsed Platinum-sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Not yet recruiting NCT03905902 Phase 3
10 Interferon Gamma-1b in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First Line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma. Terminated NCT00047632 Phase 3 Interferon gamma-1b
11 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
12 A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Unknown status NCT02437812 Phase 2 Metformin;Paclitaxel;Carboplatin
13 A Phase II Evaluation of Dalantercept (NSC #757172), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Unknown status NCT01720173 Phase 2
14 A Phase II Evaluation of CT-2103 in the Third-Line Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer Completed NCT00045682 Phase 2 Paclitaxel Poliglumex
15 A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00093626 Phase 2 Sorafenib Tosylate
16 Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Completed NCT00072566 Phase 2 Cyclophosphamide
17 A Phase II Evaluation of Karenitecin in the Third-Line Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00054119 Phase 2 Cositecan
18 A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors Completed NCT00561795 Phase 2 pazopanib (GW786034);carboplatin;paclitaxel
19 Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol Completed NCT01519869 Phase 2 neoadjuvant chemotherapy
20 A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00459290 Phase 2 mifepristone
21 A Phase II Evaluation of Vorinostat, (SAHA, NCI-Supplied Agent [NSC #701852]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00132067 Phase 2 vorinostat
22 A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00113373 Phase 2 lapatinib ditosylate
23 A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338) In Combination With Cisplatin (Commercially Available: NSC # 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma Completed NCT00081276 Phase 2 triapine;cisplatin
24 A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma Completed NCT00034151 Phase 2 S-8184 Paclitaxel Injectable Emulsion
25 A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00023699 Phase 2 gefitinib
26 A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma. Completed NCT01196559 Phase 2 Vinorelbine and Gemcitabine
27 A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00429793 Phase 2 temsirolimus
28 A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma Completed NCT00420381 Phase 2 enzastaurin
29 A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00407563 Phase 2 Bevacizumab;Abraxane
30 A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00388037 Phase 2 sunitinib malate
31 A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00004012 Phase 2 capecitabine
32 A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT01468909 Phase 2 Paclitaxel;Pazopanib Hydrochloride
33 A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT01039207 Phase 2
34 A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma Completed NCT00436644 Phase 2 Lapatinib;Topotecan
35 Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00183794 Phase 2 Docetaxel and Gemcitabine
36 A Phase II Trial of Bevacizumab (NSC# 704865) and OSI-774 (NSC# 718781) In Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT00126542 Phase 2 erlotinib hydrochloride
37 A Multicenter, Single-Arm, Phase II Trial of Bevacizumab in Subjects With Platinum-Resistant Epithelial Carcinoma of the Ovary or Primary Peritoneal Carcinoma for Whom Subsequent Doxil or Topotecan Therapy Has Failed Completed NCT00097019 Phase 2 bevacizumab
38 A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma Completed NCT00093496 Phase 2 gemcitabine hydrochloride;tanespimycin
39 A Phase II Evaluation Of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma Completed NCT00041041 Phase 2 imatinib mesylate
40 Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00026091 Phase 2 fenretinide
41 A Phase I/II Trial fo Intravenous CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00017017 Phase 1, Phase 2 paclitaxel poliglumex
42 A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission Completed NCT01246440 Phase 2 Catumaxomab
43 A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma Completed NCT00461786 Phase 2 pemetrexed
44 A Phase II Evaluation of Enzastaurin (Lilly IND # 60, 933) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00407758 Phase 2 enzastaurin hydrochloride
45 A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma Completed NCT00193297 Phase 2 Topotecan;Paclitaxel;Carboplatin
46 Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma Completed NCT00179712 Phase 1, Phase 2 CC-5013;topotecan
47 Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen Completed NCT00112957 Phase 2
48 A Phase II Evaluation Of Pemetrexed (ALIMTA LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma Completed NCT00087087 Phase 2 pemetrexed disodium
49 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
50 A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00022659 Phase 2

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

Anatomical Context for Primary Peritoneal Carcinoma

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

40
Ovary, Endothelial, Skin, Eye, Lymph Node

Publications for Primary Peritoneal Carcinoma

Articles related to Primary Peritoneal Carcinoma:

(show top 50) (show all 344)
# Title Authors PMID Year
1
Laparoscopic resection of single site pelvic side wall recurrence 6 years after stage IIIc high grade serous primary peritoneal cancer. 61
33718559 2021
2
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. 61
33318079 2021
3
Breast Metastasis of Primary Peritoneal Carcinoma Demonstrated on FDG PET/CT. 61
33795593 2021
4
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. 61
33804587 2021
5
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. 61
33357510 2021
6
Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. 61
33490221 2020
7
Primary retroperitoneal serous adenocarcinoma: A case report of rare malignancy with literature review. 61
33402586 2020
8
Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. 61
32709535 2020
9
Primary peritoneal carcinoma presenting as a case of ascites. 61
33409218 2020
10
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. 61
32808504 2020
11
Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature. 61
32832298 2020
12
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. 61
32247603 2020
13
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. 61
32669924 2020
14
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). 61
32083163 2020
15
Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study. 61
32206654 2020
16
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. 61
31986452 2020
17
Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. 61
31768818 2020
18
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). 61
32337492 2020
19
A Case of Significant Response to Olaparib in a Patient with Primary Peritoneal Carcinosarcoma Diagnosed by Laparoscopic Surgery. 61
32850164 2020
20
Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. 61
31699802 2020
21
Primary peritoneal carcinoma with late-phase pulmonary metastases: a case report. 61
31823088 2019
22
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. 61
31791688 2019
23
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). 61
31420412 2019
24
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. 61
31082382 2019
25
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. 61
31216226 2019
26
Removal of the entire internal iliac vessel system is a feasible surgical procedure for locally advanced ovarian carcinoma adhered firmly to the pelvic sidewall. 61
30891652 2019
27
Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers. 61
30885671 2019
28
Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis from rare etiologies. 61
30760409 2019
29
TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. 61
30668753 2019
30
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. 61
30587441 2019
31
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. 61
30522700 2019
32
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients. 61
29782365 2019
33
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies. 61
31346352 2019
34
A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation. 61
31223512 2019
35
Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism. 61
31807285 2019
36
[A Case of Multiple Laparoscopic Surgeries Performed for Disseminated Peritoneal Recurrence of Primary Peritoneal Carcinoma]. 61
30692361 2018
37
Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. 61
29623583 2018
38
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. 61
30135020 2018
39
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma. 61
30238835 2018
40
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. 61
29773661 2018
41
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? 61
29933927 2018
42
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). 61
29739622 2018
43
Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. 61
29324533 2018
44
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. 61
29500276 2018
45
[A Case of Splenic Metastasis from Serous Surface Papillary Carcinoma of the Peritoneum Treated by Laparoscopic Splenectomy]. 61
29650839 2018
46
Outcome of elevated CA125 values from primary care following implementation of ovarian cancer guidelines. 61
29029123 2018
47
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review. 61
29094253 2018
48
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 61
29242937 2018
49
Cauda equina syndrome secondary to leptomeningeal metastases from recurrent primary peritoneal carcinoma. 61
29515655 2018
50
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? 61
29659587 2018

Variations for Primary Peritoneal Carcinoma

Cosmic variations for Primary Peritoneal Carcinoma:

9 (show top 50) (show all 5397)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM142560558 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.727C>T p.R243W 17:7673776-7673776 6
2 COSM122271411 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.200G>A p.G67E 17:7674935-7674935 6
3 COSM121876472 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.448C>T p.R150W 17:7673776-7673776 6
4 COSM143156843 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.266G>A p.R89Q 17:7674220-7674220 6
5 COSM111804340 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.755T>C p.L252P 17:7674208-7674208 6
6 COSM142647957 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.556G>T p.V186F 17:7674290-7674290 6
7 COSM105689382 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
8 COSM143158609 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.*131C>T p.? 17:7670685-7670685 6
9 COSM122734065 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.200G>A p.G67E 17:7674935-7674935 6
10 COSM144087276 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.367C>T p.R123W 17:7673776-7673776 6
11 COSM111758876 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 17:7673776-7673776 6
12 COSM142560107 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.479G>A p.G160E 17:7674935-7674935 6
13 COSM142563486 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.892C>T p.R298C 17:7670700-7670700 6
14 COSM105620035 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>G p.Y220C 17:7674872-7674872 6
15 COSM143961018 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.358G>A p.G120R 17:7673785-7673785 6
16 COSM121896990 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.439G>A p.G147R 17:7673785-7673785 6
17 COSM142846793 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.845G>A p.R282Q 17:7673775-7673775 6
18 COSM143370725 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.479G>A p.G160E 17:7674935-7674935 6
19 COSM144134046 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.175G>A p.V59M 17:7674879-7674879 6
20 COSM111760509 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1024C>T p.R342* 17:7670685-7670685 6
21 COSM111835509 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 17:7673563-7673563 6
22 COSM121938537 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.256G>A p.V86M 17:7674879-7674879 6
23 COSM144665820 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.728G>A p.R243Q 17:7673775-7673775 6
24 COSM144094943 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.295G>A p.E99K 17:7674191-7674191 6
25 COSM144090615 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.319G>A p.G107R 17:7673824-7673824 6
26 COSM144712053 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.535G>A p.V179M 17:7674879-7674879 6
27 COSM121953255 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.434G>A p.C145Y 17:7673790-7673790 6
28 COSM144087044 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.119G>A p.G40E 17:7674935-7674935 6
29 COSM142572611 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.728G>A p.R243Q 17:7673775-7673775 6
30 COSM143378316 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.542A>C p.Y181S 17:7674872-7674872 6
31 COSM144358367 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.535G>A p.V179M 17:7674879-7674879 6
32 COSM93243863 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
33 COSM144122349 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.278T>C p.L93P 17:7674208-7674208 6
34 COSM106124152 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 17:7673563-7673563 6
35 COSM111818396 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
36 COSM142841426 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.796G>A p.G266R 17:7673824-7673824 6
37 COSM142565177 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.679G>A p.G227R 17:7673824-7673824 6
38 COSM143948172 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.319G>A p.G107R 17:7673824-7673824 6
39 COSM142842684 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>C p.Y220S 17:7674872-7674872 6
40 COSM106137701 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.673G>T p.V225F 17:7674290-7674290 6
41 COSM122282054 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.376G>A p.E126K 17:7674191-7674191 6
42 COSM106110356 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
43 COSM143950005 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.182A>C p.Y61S 17:7674872-7674872 6
44 COSM143414845 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.638T>C p.L213P 17:7674208-7674208 6
45 COSM143384913 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.728G>A p.R243Q 17:7673775-7673775 6
46 COSM122797738 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.256G>A p.V86M 17:7674879-7674879 6
47 COSM87898714 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 17:7673776-7673776 6
48 COSM142839999 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.*116C>T p.? 17:7670700-7670700 6
49 COSM144148432 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.488C>T p.P163L 17:7673563-7673563 6
50 COSM143156752 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.119G>A p.G40E 17:7674935-7674935 6

Expression for Primary Peritoneal Carcinoma

Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for Primary Peritoneal Carcinoma

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 VEGFA TP53 RET MUC16 IL10 IFNG
2
Show member pathways
13.46 VEGFA TP53 IL10 IFNG ERBB2 EGFR
3
Show member pathways
13.13 TP53 IL10 IFNG EGFR CXCL8 CXCL10
4
Show member pathways
13.02 VEGFA TP53 RET IL10 IFNG ERBB2
5
Show member pathways
12.76 VEGFA TP53 RET ERBB2 EGFR BRCA2
6
Show member pathways
12.64 TP53 PGR ERBB2 EGFR BRCA2 BRCA1
7
Show member pathways
12.54 TP53 RET ERBB2 EGFR BRCA2 BRCA1
8
Show member pathways
12.48 TP53 IL10 IFNG ERBB2 EGFR
9 12.44 TP53 ERCC1 BRCA2 BRCA1
10 12.32 VEGFA RET ERBB2 EGFR
11 12.29 VEGFA TP53 MIR195 ERBB2 EGFR BRCA1
12 12.24 VEGFA TP53 ERBB2 EGFR
13
Show member pathways
12.17 TP53 IL10 IFNG EGFR CXCL8
14 12.09 VEGFA TP53 IFNG EGFR
15 12.08 VEGFA RET IL10 CXCL8
16 11.99 VEGFA TP53 EGFR BRCA2 BRCA1
17 11.95 VEGFA TP53 RET IFNG ERBB2 EGFR
18 11.88 VEGFA TP53 IL10 CXCL8
19 11.85 VEGFA IFNG ERBB2 EGFR
20
Show member pathways
11.81 VEGFA ERBB2 EGFR
21 11.81 VEGFA IFNG CXCL8
22 11.81 ERCC1 BRCA2 BRCA1
23
Show member pathways
11.75 TP53 BRCA2 BRCA1
24 11.74 TP53 IFNG CXCL8
25 11.64 TP53 ERCC1 ERBB2 BRCA1
26 11.63 TP53 ERBB2 BRCA1
27 11.63 TP53 IFNG EGFR CXCL8 CXCL10
28
Show member pathways
11.61 VEGFA IFNG CXCL8
29 11.58 TP53 RET ERBB2 EGFR
30 11.53 IFNG CXCL8 BRCA1
31 11.49 TP53 IFNG EGFR
32 11.48 IL10 IFNG CXCL8
33 11.46 IL10 CXCL8 CXCL10
34 11.45 VEGFA RET EGFR
35 11.38 VEGFA TP53 CXCL8 BRCA1
36 11.22 VEGFA TP53 ERBB2 EGFR CXCL8
37 10.96 IL10 ERBB2 EGFR CXCL8 CXCL10

GO Terms for Primary Peritoneal Carcinoma

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 VEGFA RET PGR IL10 ERBB2 EGFR
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 VEGFA TP53 PGR IL10 EGFR CXCL10
3 positive regulation of cell proliferation GO:0008284 10.01 VEGFA IFNG ERBB2 EGFR CXCL10
4 positive regulation of transcription, DNA-templated GO:0045893 9.99 TP53 RET IL10 EGFR BRCA2 BRCA1
5 positive regulation of cell migration GO:0030335 9.9 VEGFA RET EGFR CXCL10
6 positive regulation of protein phosphorylation GO:0001934 9.88 VEGFA IFNG ERBB2 EGFR
7 negative regulation of gene expression GO:0010629 9.85 VEGFA TP53 PGR IFNG CXCL8
8 positive regulation of protein kinase B signaling GO:0051897 9.84 VEGFA RET ERBB2 EGFR
9 cytokine-mediated signaling pathway GO:0019221 9.83 VEGFA TP53 IL10 CXCL8 CXCL10
10 positive regulation of kinase activity GO:0033674 9.77 RET ERBB2 EGFR
11 positive regulation of epithelial cell proliferation GO:0050679 9.76 VEGFA ERBB2 EGFR
12 positive regulation of MAP kinase activity GO:0043406 9.74 VEGFA ERBB2 EGFR
13 nucleotide-excision repair GO:0006289 9.65 TP53 ERCC1 BRCA2
14 positive regulation of signaling receptor activity GO:2000273 9.63 IL10 IFNG
15 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 TP53 EGFR
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 IFNG
17 response to molecule of bacterial origin GO:0002237 9.62 IL10 CXCL8
18 chromosome organization GO:0051276 9.58 TP53 ERCC1 BRCA2
19 negative regulation of ERBB signaling pathway GO:1901185 9.56 ERBB2 EGFR
20 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.55 VEGFA TP53
21 response to gamma radiation GO:0010332 9.54 TP53 CXCL10 BRCA2
22 chordate embryonic development GO:0043009 9.52 BRCA2 BRCA1
23 response to X-ray GO:0010165 9.5 TP53 ERCC1 BRCA2
24 positive regulation of gene expression GO:0010628 9.5 VEGFA TP53 RET IFNG ERBB2 CXCL8
25 double-strand break repair GO:0006302 9.46 TP53 ERCC1 BRCA2 BRCA1
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 BRCA2 BRCA1
27 negative regulation of mitotic cell cycle GO:0045930 8.92 TP53 MIR195 IL10 EGFR

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.43 TP53 ERBB2 EGFR
2 TFIID-class transcription factor complex binding GO:0001094 9.16 TP53 ERCC1
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 RET ERBB2 EGFR
4 cytokine activity GO:0005125 9.02 VEGFA IL10 IFNG CXCL8 CXCL10

Sources for Primary Peritoneal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....